Quadruple therapy for eradication of Helicobacter pylori

Table 1 Baseline characteristics of the patients

Group	No. of patients	Age (yr)	Male1	Female1	Chronic erosive gastritis2	Gastric ulcer2	Duodenal ulcer2
Experimental treatment	78	44.5	41	37	34	28	16
Standard treatment	69	43.5	38	31	31	17	21

¹χ² = 0.093, P > 0.05;

²χ² = 2.96, P > 0.05.

Table 2 Helicobacter pylori eradication rate in the two groups

Group	Eradication	No eradication	Follow-up lost	Eradication rate1 (PP) (95%CI)	Eradication rate2 (ITT) (95%CI)
Experimental treatment group	67	4	7	94% (88%-99%)	86% (78%-94%)
Standard triple treatment	46	17	6	74% (64%-84%)	67% (57%-77%)

¹χ² = 12.10, P < 0.05;

²χ² = 7.615, P < 0.05. PP: Per-protocol; ITT: Intention-to-treat.

Table 3 Helicobacter pylori eradication rates in relation to disease n (%)

Group	Chronic erosive gastritis	Gastric ulcer	Duodenal ulcer
Experimental treatment	29 (34)	24 (28)	14 (16)
Standard treatment	21 (31)	11 (17)	14 (21)

χ² = 2.29, P > 0.05

Table 4 Side effect profile of patients

Group	No adverse reactions	Abdominal pain	Nausea	Vomiting	Dry throat	Bloating	Dizziness	Total
Experimental treatment	58	8	10	6	4	5	7	40
Standard triple	55	7	6	5	3	2	1	24
Total episodes	113	15	16	11	7	7	8	64

χ² = 2.13, P > 0.05.